News Search Results
May 07, 2025, 08:00 ET Corero's 2025 Threat Intelligence Report Reveals Strategic Shifts in DDoS Tactics and Rising Operational Strain for Defenders
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, released its 2025 Threat Intelligence Report, offering new insight
More news about: Corero Network Security
May 06, 2025, 16:01 ET Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
its opt-in right related to the development and commercialization of ocadusertib (previously R552) for the treatment of non-central nervous system (CNS) diseases. As a result of this notification, in the second quarter of 2025, Rigel expects to recognize approximately $40.0 million
More news about: Rigel Pharmaceuticals, Inc.
May 06, 2025, 08:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
May 05, 2025, 07:00 ET PTC518 PIVOT-HD Study Achieves Primary Endpoint
Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS). Following 12 months, patients were eligible to
More news about: PTC Therapeutics, Inc.
May 01, 2025, 17:37 ET SK Life Science Labs Announces the Publication in Nature Communications of its Breakthrough Research on Molecular Glue Discovery to Advance Cancer Immunotherapy
Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), today announced the publication of its research in the journal,
More news about: SK Life Science Labs
May 01, 2025, 17:31 ET EPIDIOLEX Continues to Lead the Way in Cannabinoid-Based Epilepsy Treatment | DelveInsight
drug profiles, including clinical and non-clinical stage products, and the key DEE companies, including Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen,
More news about: DelveInsight Business Research, LLP
May 01, 2025, 16:18 ET Cohen & Steers, Inc. Declares Quarterly Dividend
May 1, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the second quarter of 2025 in the amount of $0.62 per share of common stock payable on
More news about: Cohen & Steers, Inc.
May 01, 2025, 12:03 ET Corero Network Security anuncia a primeira ativação dos NTDs 3400 em funcionamento e eperação no mundo
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), especialista em proteção contra negação de serviço distribuída (DDoS), anunciou hoje que a operadora brasileira de telecomunicações
More news about: Corero Network Security
May 01, 2025, 11:52 ET Corero Network Security anuncia el primer despliegue de producción mundial del NTD3400
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), especialista en protección contra ataques de denegación de servicio distribuidos (DDoS), ha anunciado hoy que
More news about: Corero Network Security
May 01, 2025, 11:49 ET Corero Network Security Announces First Global Production Deployment of NTD3400
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced that Brazilian telecommunications provider
More news about: Corero Network Security
May 01, 2025, 10:27 ET New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent
More news about: Indivior PLC
May 01, 2025, 09:00 ET SUMMIT CLINICAL RESEARCH ACQUIRES HOUSTON RESEARCH INSTITUTE AND DEEPENS LEADERSHIP TEAM TO ACCELERATE GROWTH AND ENHANCE SCIENTIFIC EXPERTISE
site management organization with 15 sites across the U.S., focused on executing complex clinical trials within metabolic and central nervous system (CNS) disorders. Pinnacle leverages its therapeutic expertise to drive best-in-class clinical trial outcomes. Led by a renowned physician team, Pinnacle focuses
More news about: LongueVue Capital
Apr 30, 2025, 13:10 ET Preclinical Study from Children's Hospital of Philadelphia Highlights Innovative Approach to Replacing Brain Cells in the Treatment of Leukodystrophies
Pennsylvania announced the first ever direct approach to the depletion and replacement of microglia, the native immune cells of the central nervous system (CNS). The approach leverages microglial replacement in Krabbe disease to demonstrate its broader therapeutic potential across other neurological conditions.
More news about: Children's Hospital of Philadelphia
Apr 30, 2025, 08:00 ET GT Medical Technologies Welcomes Second GammaTile® Center of Excellence Designation
recognized with this achievement: Imran Mohiuddin, MD, PhD, Radiation Oncologist, Director of CNS Radiosurgery, Co-Director of Gamma Knife®Christopher Baker, MD, NeurosurgeonMichael Bellew,
More news about: GT Medical Technologies
Apr 30, 2025, 07:30 ET Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid
disease—making it an attractive target for CNS delivery in disorders like Rett syndrome. Developed by Apertura's academic founder, Dr. Ben Deverman, Director of Vector Engineering at the Broad Institute, TfR1 CapX has shown strong CNS selectivity in preclinical studies, achieving
More news about: Apertura Gene Therapy
Apr 29, 2025, 13:10 ET Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer
Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025
More news about: Transneural Therapeutics, Inc.
Apr 29, 2025, 13:09 ET Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Apr 29, 2025, 10:05 ET Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.
Ingredients Market - Application Outlook (Revenue, USD Billion, 2018 - 2030) Cardiovascular DiseasesOncologyCNS and NeurologyOrthopedicEndocrinologyPulmonologyGastroenterologyNephrologyOphthalmologyOthersActive
More news about: Grand View Research, Inc.
Apr 29, 2025, 07:00 ET Corero Network Security Wins 2025 Global InfoSec Award for "Best Service for a DDoS Protection Solution"
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial-of-service (DDoS) protection specialists, today announced it has been named "Best Service for a DDoS Protection
More news about: Corero Network Security
Apr 28, 2025, 20:05 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Apr 28, 2025, 18:23 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Apr 28, 2025, 18:07 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Apr 28, 2025, 18:07 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Apr 28, 2025, 18:05 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Apr 28, 2025, 18:04 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.